World BioPharm Forum
June 22-24, 2022
FUJIFILM Diosynth Biotechnologies is delighted to be presenting at World Biopharm Forum, Lady Margaret Hall, University of Oxford, UK, June 22-24, 2022.
Join Us Thursday – June 23rd at 3pm
Nick Hutcinson, Business Steering Group Leader for Mammalian Cell Culture, FUJIFILM Diosynth Biotechnologies will be presenting on A 500-L continuous mAb biomanufacturing platform.
- Continuous processing has often been discussed within the biopharmaceutical industry as a means of increasing productivity, product quality or both. Yet in reality many biopharmaceutical companies still expect their antibody candidate to be manufactured in a fed-batch production system. This is, in part, due to a lack of available, proven, large-scale, continuous biomanufacturing platforms. Fujifilm Diosynth Biotechnologies (FDB) has developed and demonstrated its MaruXTM continuous platform at the 500-L scale. This scale is perfectly suited for clinical trials supply and has the potential to be scaled-up to meet commercial demand for therapeutic antibodies.In this presentation we will describe the MaruXTM platform and present data from our successful proof-of-concept run. We will explain why we believe continuous manufacturing should be evaluated at the cell line development stage and implemented during early phase process development. Finally, we will share with the audience our plans for implementing the MaruXTM platform into GMP manufacturing facilities.